Pharmacopoeias To Aid Vaccine Creation And Research Further

The mRNAVAC Working Party was established by the European Pharmacopoeia Commission to start developing standards of quality to support the developing area of messenger RNA (mRNA) vaccines.

The first job for the newly formed Working Party will be to produce a comprehensive plan for future guidelines covering these vaccinations and their constituents. The recent EDQM Symposium on Nanomedicines’ views and suggestions will be taken into consideration, as will the knowledge obtained from using these vaccinations during the COVID-19 pandemic, which saw the first regulatory approval of mRNA vaccines.

European Pharmacopoeia is looking for professionals to join the party who have expertise in the development of mRNA vaccines and the testing or QC of either completed products or their components.